高级检索
当前位置: 首页 > 详情页

Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan 430030, Hubei Province, Peoples R China [2]Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing 100029, Peoples R China [3]Chinese PIA, Hosp 5, Dept Gastroenterol, Yinchuan, Ningxia Provinc, Peoples R China
出处:
ISSN:

关键词: Gefitinib EGFR SNP Lung adenocarcinoma Survival

摘要:
Aim: As a novel molecularly targeting agent for non-small-cell lung cancer (NSCLC), Gefitinib can block its tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Genetic variations in EGFR may affect its protein function or expression and lead to diverse outcomes in NSCLC patients after Gefitinib therapy. Therefore, this prospective study examined whether EGFR single nucleotide polymorphisms (SNPs) are associated with different survival time in advanced lung adenocarcinoma patients treated with Gefitinib. Methods: One hundred and twenty-eight patients with stage IIIB or IV lung adenocarcinoma receiving Gefitinib target therapy between 2008 and 2010 were recruited in this study. Six EGFR haplotype-tagging SNPs were genotyped by the Sequenom MassArray system. Survival by different genotypes was compared using Kaplan-Meier methods. Cox proportional hazards models were applied to estimate the effect of prognostic factors on overall survival (OS) and progression-free survival (PFS). Results: After the median 16.6 months of follow-up, the unfavorable EGFR rs2293347AA or GA genotype was significantly correlated with shorter OS (AA vs. GG: 2.0 vs. 21.0 months; hazard ratio (HR) = 2.44, 95% confidence interval (CI) = 1.06-5.56; P = 0.036; GA vs. GG: 15.0 vs. 21.0 months; HR = 1.75, 95%CI = 1.08-2.86, P = 0.025) compared with the favorable rs2293347GG genotype. The prognostic significance of EGFR rs4947492 polymorphism on OS also existed (GG carriers vs. AA carriers: median OS = 24.6 vs. 14.9 months, HR = 0.29, 95%CI = 0.10-0.83, P = 0.021). No significant associations were found among other EGFR SNPs and survival. Conclusion: EGFR rs2293347 and rs4947492 SNPs might be potential predictive markers of OS in advanced lung adenocarcinoma patients treated with Gefitinib. (c) 2013 Elsevier B.V. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 3 区 生物
小类 | 4 区 遗传学
最新[2025]版:
大类 | 3 区 生物学
小类 | 3 区 遗传学
JCR分区:
出版当年[2011]版:
Q3 GENETICS & HEREDITY
最新[2023]版:
Q2 GENETICS & HEREDITY

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan 430030, Hubei Province, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan 430030, Hubei Province, Peoples R China [*1]Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Jiefang Ave 1095, Wuhan 430030, Hubei Province, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:591 今日访问量:0 总访问量:443 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)